AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Columbia Care Reports Third Quarter 2019 Financial Results Including 123% Revenue Growth on a Year-over-Year Basis

November 5, 2019

NEW YORK--(BUSINESS WIRE)--Nov 5, 2019--

Columbia Care Inc. (NEO:CCHW) (OTCQX:CCHWF) (FSE:3LP) (“Columbia Care” or the “Company”), one of the largest fully integrated operators in the global medical cannabis industry with licenses across the US and EU, today reported financial and operating results for its third quarter ended September 30, 2019. All financial information is provided in US dollars unless otherwise indicated.

Third Quarter 2019 Financial Highlights

Subsequent to the end of the Third Quarter 2019, the Company:

“We are delighted to report such strong financial and operational performance for the quarter. Despite continued regulatory challenges, we have maintained our focus on driving towards profitability in existing markets, opening new markets, and innovating to ensure we have better and differentiated products and services. In addition, Columbia Care continues to deliver on its key initiatives, and with today’s announcement of our first acquisition, The Green Solution, we enter a new phase of the Company’s growth cycle, using disciplined M&A as a complement to our core strategy. The combination of these approaches will enable us to maintain our dominant position in the US and global cannabis marketplace,” said Nicholas Vita, chief executive officer of Columbia Care. “Our fundamentals continue to be strong with $22.1M revenue reported in the third quarter, a 123% increase from the prior year, and with almost $85M in cash and no debt on our balance sheet at quarter end, Columbia Care stands apart in its ability to fund existing growth initiatives while having access to multiple financing options for opportunistic activities. By maintaining financial discipline and focusing on our operational execution, we expect our efforts to translate into strong results for the remainder of 2019 and beyond.”

Discussion of Third Quarter 2019 and First Nine Months 2019 Results

Revenue for the third quarter of 2019 totaled $22.1 million, an increase of 123% compared to the third quarter of 2018. Revenue for the nine-month period ended September 30, 2019 was $54.3 million, an increase of 92% compared the prior year period.

Revenue increased due to the Company’s organic growth in its licensed jurisdictions coupled with higher consumer demand for Columbia Care’s medical and wellness cannabis products.

Excluding the impact of fair value adjustments for biological assets, gross profit for the third quarter of 2019 was $5.3 million, an increase of 42% compared to the third quarter of 2018. For the nine-month period ended September 30, 2019, gross profit, excluding the impact of fair value adjustments for biological assets, was $15.1 million, an increase of 21% compared to the prior year period.

The Company’s gross profit for the third quarter of 2019 was $15.7 million, an increase of 39% compared to the third quarter of 2018. For the nine-month period ended September 30, 2019, gross profit was $18.7 million, an increase of 6% compared to the prior year period.

Net loss for the third quarter of 2019 was $19.9 million, compared to $5.3 million for the prior year period, primarily due to higher operating expenses related to equity-based compensation expense, salary and benefit expenses and professional fees. Net loss for the nine-month period ended September 30, 2019 was $78.7 million, compared to $19.2 million for the prior year period, primarily due to equity-based compensation expense, professional fees, listing fee expense and salary and benefit expense.

Adjusted EBITDA for the third quarter of 2019 was ($11.3) million, compared to ($4.2) million for the prior year period. Adjusted EBITDA for the nine-month period ended September 30, 2019 was ($33.0) million, compared to ($8.2) million for the prior year period. Changes in Adjusted EBITDA were primarily driven by higher operating expenses. See “Non-IFRS Financial Measures.”

As of September 30, 2019, the Company had $84.5 million cash on hand and carried no debt.

Conference Call and Webcast Details
The Company will report complete financial results for the third quarter 2019 on Tuesday, November 5, 2019 at 4:30 p.m. EST. To access the live conference call via telephone, please dial 1-877-407-8914 (U.S. callers) or 1-201-493-6795 (international callers), no passcode is required. A live audio webcast of the call will also be available in the Investor Relations section of the Company’s website at https://ir.col-care.com/.

A replay of the audio webcast will be available in the Investor Relations section of the Company’s website approximately 2 hours after completion of the call and will be archived for 30 days.

Non-IFRS Financial Measures
In this press release, Columbia Care refers to certain non-IFRS financial measures, such as Adjusted EBITDA and gross profit excluding changes in fair value of biological assets. These measures do not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. Columbia Care considers certain non-IFRS measures to be meaningful indicators of the performance of its business. A reconciliation of such non-IFRS financial measures to their nearest comparable IFRS measure is included in this press release.

About Columbia Care Inc.
Columbia Care Inc. is one of the largest and most experienced multi-state operators in the medical cannabis industry, with licenses in 15 jurisdictions in the US and the EU. With over 1.4 million in sales transactions since its inception, Columbia Care is a patient-centered organization setting the standard for compassion, professionalism, quality, caring and innovation, working in collaboration with some of the most renowned and innovative teaching hospitals and medical centers in the world. The Company is committed to providing the type of education and transparency patients deserve and quality of product that clinicians expect. For more information on Columbia Care, please visit www.col-care.com.

Caution Concerning Forward-Looking Statements
This press release contains certain statements that constitute forward-looking information within the meaning of applicable securities laws (“forward-looking statements”). Statements concerning Columbia Care’s objectives, goals, strategies, priorities, intentions, plans, beliefs, expectations and estimates, and the business, operations, financial performance and condition of Columbia Care are forward-looking statements. The words “believe”, “expect”, “anticipate”, “estimate”, “intend”, “may”, “will”, “would”, “could”, “should”, “continue”, “plan”, “goal”, “objective”, and similar expressions and the negative of such expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Certain material factors and assumptions were applied in providing these forward-looking statements. Forward-looking information involves numerous assumptions, including the ability of the Company to obtain certain third party consents, permits and approvals; the ability of Columbia Care to meet its dispensary targets, including the ability to negotiate additional lease arrangements satisfactory to the Company; the ability of the Company to complete all planned construction in a timely manner; and the ability of the Company to identify and attract qualified staff. Projections may be impacted by macroeconomic factors, in addition to other factors not controllable by the Company. Columbia Care has also made certain general industry assumptions in the preparation of such forward-looking statements. Management believes that the expectations reflected in forward-looking statements are based upon reasonable assumptions; however, Management can give no assurance that actual results will be consistent with these forward-looking statements. Not all factors which affect the forward-looking information are known, and actual results may vary from the projected results in a material respect and may be above or below the forward-looking information presented in a material respect.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Columbia Care’s actual results, performance or achievements, or developments in its industry, to differ materially from the anticipated results, performance, achievements or developments expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in Columbia Care’s final prospectus dated March 21, 2019 (the “Prospectus”) and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in the Prospectus could cause actual events or results to differ materially from those described in any forward-looking information. Forward-looking statements are based on management’s current plans, estimates, projections, beliefs and opinions, and Columbia Care does not undertake any obligation to update forward-looking statements should assumptions related to these plans, estimates, projections, beliefs and opinions change except as required by applicable securities laws. All of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Columbia Care.

TABLE 1 - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in US $ thousands, except share and per share figures, unaudited)
 
Three Months EndedNine Months Ended
September 30, 2019September 29, 2018September 30, 2019September 29, 2018
 
Revenue

 $

                             22,120

 

 $

                               9,925

 

 $

                             54,287

 

 $

                             28,345

 

Production costs

 

                              (16,830

)

 

(6,189

)

 

                              (39,167

)

 

                              (15,821

)

 
Gross profit before fair value adjustments

 

5,290

 

 

3,736

 

 

15,120

 

 

12,524

 

Fair value adjustments biological assets, net

 

10,389

 

 

7,575

 

 

3,590

 

 

5,194

 

 
Gross profit

 

15,679

 

 

11,311

 

 

18,710

 

 

17,718

 

Operating expenses

 

(33,819

)

 

(15,056

)

 

                              (95,013

)

 

                              (32,233

)

 
Operating loss

 

                              (18,140

)

 

(3,745

)

 

                              (76,303

)

 

                              (14,515

)

Other expense, net

 

    (458

)

 

(1,664

)

 

    (176

)

 

(3,585

)

Income tax (expense) benefit

 

(1,264

)

 

        95

 

 

(2,233

)

 

(1,141

)

 
Net loss  

 

                              (19,862

)

 

(5,314

)

 

                              (78,712

)

 

                              (19,241

)

Net loss attributable to non-controlling interests

 

(1,599

)

 

   (368

)

 

(1,947

)

 

    (835

)

 
Net loss attributable to Columbia Care shareholders

 $

                          (18,263

)

 $

                            (4,946

)

 $

                          (76,765

)

 $

                          (18,406

)

 
Weighted average common shares outstanding - basic and diluted

 

                     216,269,530

 

 

                     163,352,801

 

 

                     207,729,060

 

 

161,564,898

 

 
Earnings per common share attributable to Columbia Care shareholders - basic and diluted

 $

                               (0.08

)

 $

                               (0.03

)

 $

                               (0.37

)

 $

                               (0.11

)

TABLE 2 - RECONCILIATION OF IFRS TO NON-IFRS MEASURES
(in US $ thousands, unaudited)
 
Three Months EndedNine Months Ended
September 30, 2019September 29, 2018September 30, 2019September 29, 2018
 
Net loss  

 $

                          (19,862

)

 $

                            (5,314

)

 $

                          (78,712

)

 $

                          (19,241

)

Income tax expense (benefit)

 

  1,264

 

 

      (95

)

 

  2,233

 

 

  1,141

 

Depreciation and amortization

 

  4,231

 

 

  1,238

 

 

10,260

 

 

  3,386

 

Net interest and debt amortization

 

      350

 

 

  1,662

 

 

  1,175

 

 

  3,227

 

 
EBITDA

 $

                          (14,017

)

 $

                            (2,509

)

 $

                          (65,044

)

 $

                          (11,487

)

 
Share-based compensation

 

13,150

 

 

  5,910

 

 

24,539

 

 

  8,518

 

Fair value adjustments biological assets, net

 

                              (10,389

)

 

(7,575

)

 

(3,590

)

 

(5,194

)

Listing fee expense

 

         -  

 

 

         -  

 

 

11,071

 

 

         -  

 

 
Adjusted EBITDA

 $

                          (11,256

)

 $

                            (4,174

)

 $

                          (33,024

)

 $

                             (8,163

)

TABLE 3 - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW
(in US $ thousands, unaudited)
 
Three Months EndedNine Months Ended
September 30, 2019September 29, 2018September 30, 2019September 29, 2018
 
Net cash used in operating activities

 $

                          (11,332

)

 $

                            (2,892

)

 $

                          (53,626

)

 $

                          (17,007

)

Net cash used in investment activities

 

                              (26,714

)

 

(1,361

)

 

                              (58,119

)

 

(7,294

)

Net cash (used in) provided by financing activities

 

(2,758

)

 

12,561

 

 

                              150,010

 

 

33,917

 

Net (decrease) increase in cash

 

                              (40,804

)

 

  8,308

 

 

38,265

 

 

  9,616

 

Cash balance - beginning of period

 

                              125,310

 

 

14,605

 

 

46,241

 

 

13,297

 

Cash balance - end of period

 

84,506

 

 

22,913

 

 

84,506

 

 

22,913

 

 
TABLE 4 - CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (SELECT ITEMS)
(in US $ thousands, unaudited)
 
 
September 30, 2019December 29, 2018
 
Cash

 $

                             84,506

 $

                            46,241

Total current assets

 

                              172,286

 

                             160,122

Property and equipment, net

 

95,274

 

39,794

Right of use assets

 

42,156

 

         -  

Total assets

 

                              356,974

 

                             233,927

Total current liabilities

 

29,129

 

15,309

Total liabilities

 

71,382

 

30,238

Total equity

 

                              285,592

 

                             203,689

 

View source version on businesswire.com:https://www.businesswire.com/news/home/20191105006145/en/

CONTACT: Investors:

Gary F. Santo, Jr.

Investor Relations

+1.212.271.0915

gsanto@col-care.comMedia:

Cait Williamson, Ph.D.

LifeSci Public Relations

+1.646.751.4366

cait@lifescipublicrelations.com

KEYWORD: NEW YORK UNITED STATES NORTH AMERICA CANADA

INDUSTRY KEYWORD: MANAGED CARE HOSPITALS ALTERNATIVE MEDICINE HEALTH

SOURCE: Columbia Care Inc.

Copyright Business Wire 2019.

PUB: 11/05/2019 04:05 PM/DISC: 11/05/2019 04:05 PM

http://www.businesswire.com/news/home/20191105006145/en